Profile data is unavailable for this security.
About the company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
- Revenue in USD (TTM)5.86bn
- Net income in USD956.60m
- LocationAlexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
- Phone+1 (475) 230-2596
- Fax+1 (203) 271-8198
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ALXN:NSQ since |
|Portola Pharmaceuticals Inc||Deal completed||05 May 2020||05 May 2020Deal completed||55.77%||1.46bn|